Clinical Phase I/II trial to Investigate Preoperative Dose-Escalated Intensity-Modulated Radiation Therapy (IMRT) and Intraoperative Radiation Therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis by Falk Roeder et al.
Roeder et al. BMC Cancer 2014, 14:617
http://www.biomedcentral.com/1471-2407/14/617RESEARCH ARTICLE Open AccessClinical Phase I/II trial to Investigate Preoperative
Dose-Escalated Intensity-Modulated Radiation
Therapy (IMRT) and Intraoperative Radiation
Therapy (IORT) in patients with retroperitoneal
soft tissue sarcoma: interim analysis
Falk Roeder1,2,8*, Alexis Ulrich3, Gregor Habl2, Matthias Uhl2, Ladan Saleh-Ebrahimi1,8, Peter E Huber1,2,
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Background: To report an unplanned interim analysis of a prospective, one-armed, single center phase I/II trial
(NCT01566123).
Methods: Between 2007 and 2013, 27 patients (pts) with primary/recurrent retroperitoneal sarcomas (size > 5 cm,
M0, at least marginally resectable) were enrolled. The protocol attempted neoadjuvant IMRT using an integrated
boost with doses of 45–50 Gy to PTV and 50–56 Gy to GTV in 25 fractions, followed by surgery and IOERT
(10–12 Gy). Primary endpoint was 5-year-LC, secondary endpoints included PFS, OS, resectability, and acute/late
toxicity. The majority of patients showed high grade lesions (FNCLCC G1:18%, G2:52%, G3:30%), predominantly
liposarcomas (70%). Median tumor size was 15 cm (6–31).
Results: Median follow-up was 33 months (5–75). Neoadjuvant IMRT was performed as planned (median dose
50 Gy, 26–55) in all except 2 pts (93%). Gross total resection was feasible in all except one patient. Final margin
status was R0 in 6 (22%) and R1 in 20 pts (74%). Contiguous-organ resection was needed in all grossly resected
patients. IOERT was performed in 23 pts (85%) with a median dose of 12 Gy (10–20 Gy).
We observed 7 local recurrences, transferring into estimated 3- and 5-year-LC rates of 72%. Two were located
outside the EBRT area and two were observed after more than 5 years. Locally recurrent situation had a significantly
negative impact on local control. Distant failure was found in 8 pts, resulting in 3- and 5-year-DC rates of 63%.
Patients with leiomyosarcoma had a significantly increased risk of distant failure. Estimated 3- and 5-year-rates were
40% for PFS and 74% for OS. Severe acute toxicity (grade 3) was present in 4 pts (15%). Severe postoperative
complications were found in 9 pts (33%), of whom 2 finally died after multiple re-interventions. Severe late toxicity
(grade 3) was scored in 6% of surviving patients after 1 year and none after 2 years.
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Conclusion: Combination of neoadjuvant IMRT, surgery and IOERT is feasible with acceptable toxicity and yields good
results in terms of LC and OS in patients with high-risk retroperitoneal sarcomas. Long term follow-up seems
mandatory given the observation of late recurrences. Accrual of patients will be continued with extended follow-up.
Trial registration: NCT01566123.Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Written informed consent • Missing written informed consent
• Histologically confirmed, primary
or locally recurrent soft tissue
sarcoma of the retroperitoneal
space
• Missing histological conformation
of soft tissue sarcoma
• Judged as at least marginally
resectable
• Desmoid Tumors (aggressive
fibromatosis), Gastrointestinal
Stroma Tumors (GIST)
• Absence of distant metastases • Judged as gross incomplete or not
resectable
• Tumor size ≥ 5 cm • Incomplete staging
• Presence of distant metastases
• Prior radiation therapy to the
abdominal region
• Participation in another clinical
interventional study
• Inflammatory bowel diseaseBackground
Local control rates in patients with retroperitoneal soft
tissue sarcoma (RSTS) remain disappointing even after
gross total resection, mainly because wide margins are not
achievable in the majority of patients [1]. In contrast to
extremity sarcoma, postoperative radiation therapy (RT)
has shown limited efficacy due to difficulties in achieving
adequate dose and coverage [2]. Although intraoperative
radiation therapy (IORT) has been introduced in some
centers to overcome the dose limitations and resulted in
increased outcome [3], local failure rates are still high even
if considerable treatment related toxicity is accepted [2,3].
Compared to the postoperative approach, preoperative ra-
diation therapy could offer several benefits, including a
more precise target volume definition with smaller safety
margins, reduced toxicity to adjacent organs at risk be-
cause of their displacement through the tumor itself, a
possible devitalisation of tumor cells and the avoidance of
treatment delays due to postoperative complications [1].
The use of Intensity-modulated radiation therapy (IMRT)
further offers improved target coverage with reduced dose
to adjacent organs at risk compared to conventional
irradiation [4] and the opportunity to reduce overall treat-
ment time using an integrated boost concept with simul-
taneously increased dose per fraction to the gross tumor
volume. Since little data exists about the combination of
these approaches, we initiated this prospective, non-
randomised, single center trial [5] to investigate the value
of dose-escalated preoperative IMRT followed by surgery
with an intraoperative electron boost to reduce the local
recurrence rate without a markedly increased toxicity.
Due to the slow accrual of patients, we performed an un-
planned interim analysis to decide, if the trial should be
continued or stopped. The results are presented here.
Methods
Study design
Details of the study design have been published elsewhere
[5]. Briefly, the trial was designed as a prospective single-
center one-armed phase I/II study. Inclusion and exclu-
sion criteria are listed in Table 1. Pretreatment evaluation
included clinical examination, laboratory tests, histological
confirmation, CT or MR-imaging of the abdominal cavity,
thoracic CT, bone scan, scintirenography, evaluation of
general and technical resectability. For neoadjuvant IMRT,patients were immobilized using an individual body mask
system or a vacuum pillow. Inverse treatment planning
was based on contrast enhanced CT and MRI. The Gross
Tumor Volume (GTV) included all macroscopic tumor.
The clinical target volume (CTV) included the GTV with
a margin of 1.5 cm in all directions. A safety margin of
5 mm was added to obtain the Planning Target Volume
(PTV). Margins could be reduced with respect to anatom-
ical borders or adjacent organs at risk. The attempted dose
was 45–50 Gy to the PTV and 50–56 Gy to the GTV in
25 fractions (integrated boost concept). Doses were pre-
scribed to the median of the GTV, while the different tar-
get volumes should be surrounded by the corresponding
95% isodose line. An example of a dose distribution in a
very large tumor is shown in Figure 1. Treatment was per-
formed using step-and-shoot IMRT after stereotactic tar-
get point localisation. Setup correction was done using an
image-guided approach with an In-Room-CT on rails at
least weekly. Since October 2008 all patients have received
daily In-Room-CT pretreatment setup verification and
correction. Re-evaluation including restaging with abdom-
inal CT/MRI and assessment of toxicity was scheduled
4 weeks after the last fraction of neoadjuvant irradiation.
Gross total resection of the tumor was attempted within
2 weeks from restaging, including contiguous-organ or
Figure 1 Example for a dose distribution in a large retroperitoneal sarcoma. Left: axial view, middle: sagittal view, right: frontal view, red
line: GTV, yellow line: PTV, other coloured lines: organs at risk, legend: percentage of prescribed dose.
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IORT using a dedicated linear accelerator was directed to
the whole tumor bed with an attempted dose of 10–12 Gy
prescribed to the 90% isodose. If the complete tumor bed
could not be covered due to its large size, IORT was
directed to the intraoperatively defined high-risk region
for positive margins. Definition of the high-risk region
was done by the treating surgeon together with the radi-
ation oncologist based on macroscopic evaluation of the
resected specimen in correlation with the preoperative im-
aging. Frozen sections of the tumor bed were generally
available but not routinely used. Multiple field IORT was
considered and performed only if an overlap of the fields
could definitively be avoided. If no coverable high risk re-
gion could be defined, IORT was not performed. Regular
follow-up visits took place every 3 months after surgery
for the first 2 years and every 6 months for three further
years. They included at least clinical and laboratory exami-
nations, CT or MR-imaging of the abdominal cavity and
thoracic CT (every second visit).
Statistical and legal considerations
The primary objective was the local control rate after
5 years. Secondary objectives were progression-free sur-
vival, overall survival, acute and late toxicity, resectability
and patterns of recurrence. Local control was defined as
absence of disease progression/recurrence in the abdom-
inal cavity (except organ metastases or diffuse peritoneal
sarcomatosis). Progression-free survival (PFS) was deter-
mined as absence of local or distant recurrence/progres-
sion or death of any cause. Time to event data was
calculated from the first day of radiation treatment using
the Kaplan-Meier method. Acute and late radiation tox-
icity was assessed according to Common Terminology
Criteria for Adverse Events Version 3.0 (CTCAE 3.0).
Postoperative complications were assessed according to
the Clavien-Dindo classification [6]. Based on the initial
statistical considerations, the calculated sample size was
37 patients in the per protocol population to detect an
improvement in the 5-year local control rate from 50%
(assumption from the literature after surgery andpostoperative 3D-conformal radiation therapy) to 70%
with a power of 80%. According to the protocol, data
should be analysed separately by per protocol and full
set analysis population (defined as all patients who
started radiation therapy). The study protocol was
approved by the independent ethics committee of the
Medical Faculty at the University of Heidelberg. The
trial was carried out by adhering to local legal and regu-
latory requirements. The study complies with the Dec-
laration of Helsinki 2004, the principles of Good clinical
practice (GCP) and the German Federal Data Protection
Act. Written informed consent was obtained from each
patient prior to study entry.Patient characteristics
The current interim analysis was based on the full set ana-
lysis population after the inclusion of 27 patients between
2007 and 2013. Median age at inclusion was 60 years
(range 37–76 years) and 52% of the patients were male.
The majority of patients showed high-grade lesions
(FNCLCC G1:18%, G2:52%, G3:30%). The predominant
histology was liposarcoma (70%). Median tumor size was
15 cm (6–31 cm). For detailed patient characteristics see
Table 2.Results
Completion of planned treatment
The median follow-up was 33 months (5–75 months) for
the entire cohort, and 37 months (8–75 months) in surviv-
ing patients. Neoadjuvant IMRT was completed as planned
in 25 patients (93%) without treatment breaks > 4 days. In
two patients neoadjuvant IMRT was prematurely finished.
One suffered from local disease progression and proceeded
to immediate surgery after 13 fractions, one developed
grade 3 leukopenia and treatment was stopped after 23
fractions to avoid compromise of surgical treatment.
The median GTV and PTV volumes were 1146 ccm
(range 62 to 6763 ccm) and 2452 ccm (range 388 to 8516
ccm), respectively. A median number of 9 beams (range
5–14) with 144 segments (43 to 242) was used to deliver
Table 2 Patient characteristics
























Max grade 1 15 55
Max grade 2 7 26
Max grade 3 1 4
n: number of patients, %: percentage, FNCLCC: Federation Nationales des
Centres de Lutte Contre le Cancer, cm: centimeter.
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45 Gy (23.4 to 50 Gy) to the PTV (see Table 3).
The median time spans from the end of neoadjuvant
radiation treatment to restaging and from restaging to
surgery were 28 days (12–38 days) and 11 days (1–33
days), respectively (excluding the patient with immediate
surgery due to progression who did not receive formal
restaging). The median time from the end of neoadju-
vant radiation treatment until surgery was 39 days
(range 6–62 days).
Gross total resection was achieved as planned in 26
patients (96%). Final resection margin was R0 in 6 pa-
tients (22%) and R1 in 22 patients (74%). One patient
was judged non-resectable intraoperatively. Contiguous
organ resection to achieve grossly free margins was
required in all resected patients (see Table 3). Major ves-
sel resection and reconstruction was needed in 8 pa-
tients (30%). Major nerve resections were required in 2patients and partial resection of the psoas muscle or dia-
phragm was necessary in 9 patients (see Table 3).
IORT was performed in 23 patients (85%) including
the non-resectable patient. One patient received no
IORT due to technical reasons and in the remaining
three patients a coverable high-risk region could not be
defined intraoperatively. The median IORT dose was
12 Gy (range 10–20 Gy) with a median electron energy
of 8 MeV (range 6–12 MeV) and a median cone size of
8 cm (range 5–18 cm), see Table 3.
Oncological endpoints
We found seven local recurrences (26%), transferring
into estimated 3- and 5-year local control rates of 72%,
respectively (Figure 2). Of note, two of the recurrences
were located near but outside the EBRT areas, two were
observed after more than 5 years of follow-up and three
were found in patients with recurrent situation at inclu-
sion. Recurrent situation at inclusion was the only factor
with significantly negative impact on local control in
univariate analysis. Patients presenting in primary situ-
ation showed estimated 3- and 5-year local control rates
of 88%. Local failures were treated by surgery (with or
without IOERT) including histological confirmation in 6
patients and with palliative systemic treatment without
histological confirmation in one patient with simultan-
eously diagnosed diffuse metastatic disease. Of the two
recurrences observed after more than 5 years, one was
histologically confirmed and salvaged by surgery.
Distant failures were observed in eight patients (30%),
transferring into estimated 3- and 5-year distant control
rates of 63%, respectively (Figure 3). Seven of them oc-
curred during the first two years of follow-up. Histology
of leiomyosarcoma was the only factor with significantly
negative impact on distant control in univariate analysis.
The 3- and 5-year progression-free survival rates were
40%, respectively. Of the 16 observed events, 5 were iso-
lated local recurrences, 6 were isolated distant failures, 2
were combined failures and 3 were deaths without disease
progression. Histology of leiomyosarcoma was the only
factor with significantly negative impact on progression-
free survival. Furthermore we found a trend for improved
PFS in primary vs. recurrent situation.
Six patients died during follow-up, transferring into
estimated 3- and 5-year overall survival rates of 74%
(Figure 4), respectively. None of the tested factors
showed a significant impact on overall survival.
Toxicity
Acute radiation related toxicity was mainly hematological
and gastrointestinal. The maximum acute toxicity was
grade 1 in 10 patients (37%), grade 2 in 13 (48%) patients
and grade 3 in 4 patients (15 %). For detailed analysis see
Table 4.
Table 3 Treatment characteristics
Treatment n % n %
Neoadjuvant IMRT Surgery
Completed 25 93 Gross total 26 96
Not completed 2 7 Explo. lap 1 4
GTV volume [ccm] Resection margin
Median 1146 R0 6 22
Min 62 R1 20 74
Max 6763 Explo. Lap. 1 4
PTV volume [ccm] Cont. organ resection
Median 2452 yes 26 96
Min 388 no 1 4
Max 8516
Number of organs*
GTV dose [Gy] 0 (explo Lap) 1 4
Median 50 1 7 26
Min 26 2 8 30
Max 55 3 5 19
4 6 22
PTV dose [Gy]
Median 45 Type of organ
Min 23,4 Nephrectomy 18 67
Max 50 Hemicolectomy 16 59
Splenectomy 8 30
Number of beams Partial pancreatectomy 8 30
Median 9 Cholecystectomy 8 30
Min 5 Small bowel resection 3 11
Max 14 Rectum resection 3 11
Partial colpectomy 2 7
Number of segments Partial liver resection 1 4
Median 144 Cystectomy 1 4
Min 43 Adnexectomy 1 4
Max 242 Hysterectomy 1 4
IOERT Muscle resection
Completed 23 Yes 9 33
Not completed 4 No 18 67
Psoas 4 15
IOERT dose [Gy] Diaphragm 6 22
Median 12
Min 10 Vessel resection
Max 20 Yes 8 30
No 19 70
IOERT energy [MeV] Major artery 4 15
Median 8 Major vein 7 26
Min 6
Max 12 Nerve resection
Table 3 Treatment characteristics (Continued)
Yes 2 7
IOERT cone size [cm] No 25 93
Median 8
Min 5
Max 18 *: Cholecystectomy excluded
n:number of patients, %: percentage, IMRT: intensity-modulated radiation
therapy, GTV: gross tumor volume, PTV: planning target volume, ccm : cubic
centimetre, Gy: gray, IOERT : intraoperative electron radiation therapy, MeV :
mega electron volts, cm : centimetre, explo. Lap. : explorative laparotomy, R0:
microscopically negative, R1 : microscopically positive, cont. contiguous.
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tomotic leakage, pancreatic fistula/leakage, intra-abdominal
bleeding, sepsis and left ventricular dysfunction. The 30-
day postoperative mortality rate was 0%, but 2 patients fi-
nally died in the prolonged postoperative period. The
maximum postoperatively observed toxicity was grade 1 in
7 patients (26%), grade 2 in 10 patients (37%), grade 3a in 5
patients (18%), grade 3b in 1 patient (4%), grade 4b in 1
patient (4%) and grade 5 in 2 patients (7%). 4 patients
(15%) needed re-laparotomies (2 of them multiple ones).
One of the deceased patients developed a pancreatic/duo-
denal leakage after partial pancreatic and major vessel re-
section, but initially denied re-laparotomy and finally died
due to massive intra-abdominal bleeding 3 months later al-
though emergency surgery was performed. The other pa-
tient developed a pancreatic and multiple bowel leakages
with intraabdominal bleeding complications after multi-
visceral resection including partial pancreatectomy, neph-
rectomy, hemicolectomy and splenectomy, and finally died
after multiple re-interventions due to septic complications.
For detailed analysis see Table 5.
Observed late toxicity was mainly gastrointestinal, genito-
urinary and neurological, but generally mild. As late toxicity
may vary over time, it was analysed separately at different
time points. Patients with salvage treatments were excluded
from analysis. Suitable information was available in 16 pa-
tients at one year and 14 patients at two years. Maximum
toxicity at one year was grade 0 in 4 patients (25%), grade 1
in 7 patients (44%), grade 2 in 4 patients (25%) and grade 3
in one patient (6%). Maximum toxicity at two years was
grade 0 in 4 patients (29%), grade 1 in 7 patients (50%) and
grade 2 in 5 patients (36%). For detailed analysis see
Table 6.
Discussion and conclusions
The optimal management of retroperitoneal soft tissue
sarcomas including the role of radiation therapy has
been extensively debated in the past and remains still un-
clear. In contrast to extremity sarcoma, data from large
randomized trials regarding the optimal treatment for
retroperitoneal sarcoma is still lacking due to the rarity of
this disease and even prospective phase I/II data is rare.
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Figure 2 Local control.
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Figure 3 Distant control.
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Figure 4 Overall survival.
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spective single center series, usually covering small pa-
tients numbers treated over many years with various
combinations of surgical approaches and radiation treat-
ment modalities. Therefore, evidence gained in the much
larger studies in extremity sarcoma patients is frequently
transferred to guide treatment of retroperitoneal sarco-
mas. As margin status has been identified as an important
prognostic factor in both extremity and retroperitoneal
sarcomas [7,8] surgery with wide negative margins repre-
sents the cornerstone of curative intent approaches. How-
ever, the achievement of wide or even close negative
margins is much more difficult in the retroperitoneal
space than in the extremities, resulting in much higher
local recurrence rates after surgery alone [9]. Even with
more aggressive surgical approaches using en bloc resec-
tions of adjacent uninvolved organs, local recurrence re-
mains the dominant pattern of failure in retroperitoneal
sarcomas [10,11]. Additional radiation therapy has clearly
been shown to improve local control in extremity sarco-
mas irrespective of margin status with increasing benefits
after close or positive margin resections [7] and is there-
fore widely accepted as standard of care for these patients.
As close or positive margins are more frequent in retro-
peritoneal sarcomas, this should theoretically lead to an
even more pronounced benefit from additional radiation
therapy, but only a minority of patients is currently treatedwith this combination approach [12]. Postoperative exter-
nal beam radiation therapy was the first RT modality,
which has been investigated. But although local control
seemed to be improved in many series compared to sur-
gery alone [11,13,14], concerns have been raised mainly by
the difficulties in achieving adequate dose and target
coverage in the postoperative setting. Delivery of efficient
doses with generous margins as used in extremity sarco-
mas is often hampered by the presence of small bowel
loops in the resection cavity which would result in un-
acceptable toxicity in many cases, while reduced doses or
margins would compromise efficacy. Because of the known
dose-effect relationship which favours doses ≥55 Gy
[15,16], several institutions including ours investigated add-
itional boosting techniques like intraoperative radiation
therapy (IORT) or brachytherapy to overcome these limita-
tions [2,3,17-19]. The only randomized trial comparing dif-
ferent local treatment approaches in retroperitoneal
sarcoma showed a clear benefit favouring a combination of
postoperative EBRT (35–40 Gy) and IORT (20 Gy) com-
pared to postoperative EBRT alone (50–55 Gy) in terms of
local control (60% vs. 20%) and gastrointestinal toxicity,
while neurological toxicity was markedly increased in the
IORT arm [3]. Several non-randomized single institution
series have confirmed high rates of local control for this
combination approach with acceptable neurological toxic-
ities limiting the IORT dose to 15 Gy [2,17,18,20], but
Table 4 Acute toxicity (including the preoperative period)
Toxicity All grades Grade 1 Grade 2 Grade 3
GI
Diarrhea 11 5 4 2
Nausea 11 6 5 0
Appetite loss 4 3 1 0
Bloating 8 3 5 0
Reflux 3 2 1 0
Constipation 3 1 2 0
Hematological
Anemia 18 12 5 1
Leucopenia 9 5 3 1
Thrombopenia 8 8 0 0
Skin
Erythema 10 10 0 0
GU
Frequency/urgency 3 1 2 0
Dysuria 4 3 1 0
Bladder obstruction 1 0 1 0
Ureter obstruction 1 0 0 1
Infection 2 0 1 1
Other
Pain 6 6 0 0
Fatigue 2 1 1 0
Motor neuropathy* 1 0 1 0
Varicocele 1 0 1 0
Hypokalemia 1 1 1 1
GI: gastrointestinal, GU: genitourinary, *:transient.
Table 5 Complications in the postoperative period
Complication All grades 1 2 3a 3b 4b 5
GI
Functional bowel obstruction 5 1 3 1
Pancreatic fistula/leakage 5 5**
Intraabdominal bleeding 3 2 1
Bowel/anastomotic leakage 2 1 1




Ulcus ventriculi/duodeni 1 1
Infection* 2 1 1
Wound complication
Wound healing disturbance 5 2 1 1 1
Lymph edema 3 3




Motor neuropathy/weakness 5 5
Sensory neuropathy 5 5
GU
Renal failure 5 5
Cystitis/infection 4 4
Ureter obstruction 2 2
Urinary incontinence 1 1
Scrotal edema 1 1
Cardiac/vascular
Av block 1 1
Ventricular dysfunction 1 1
Hypertension 1 1
Deep vein thrombosis 1 1
Pulmonary
Pleural effusion 2 1 1
Pneumothorax 1 1
Hematological
Anemia 2 1 1
Leucopenia 1 1
GI: gastrointestinal, GU: genitourinary, *not leakage/fistula associated,
**managed with CT-guided drainage procedures.
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local control and toxicity, especially if compared to
extremity sarcomas. Preoperative radiation therapy offers
several possible advantages compared to the postoperative
approach. These include a possible sterilization of the
operative field against seeding, a possible thickening of
the often-present pseudocapsule easing resection and
the avoidance of repopulation through treatment delays
because of postoperative complications. However, the
main advantage seems to be the more accurate target
volume definition with the possibility of reduced safety
margins and reduced toxicity especially to small bowel
loops because of their displacement through the tumor
itself. Furthermore, the improved oxygenation could
increase radiosensitivity and lower the required dose as
known from extremity sarcomas. Some of these advan-
tages, especially regarding target coverage and reduction
of dose to adjacent organs at risk, can be further exploited
with the use of modern radiation techniques like IMRT,
VMAT or Tomotherapy as shown in several planningstudies [4,21-23], including the opportunity to reduce
overall treatment time by an integrated boost concept.
In our present study, we therefore combined the theor-
etically advantageous techniques of preoperative intensity-
modulated RT with an integrated boost concept, surgery
and IORT with the aim to achieve maximal local control.
Table 6 Late toxicity
Toxicity All grades Grade 1 Grade 2 Grade 3
1 yr 2 yrs 1 yr 2 yrs 1 yr 2 yrs 1 yr 2 yrs
GI
Diarrhea 3 2 3 2 0 0 0 0
Constipation 1 2 1 2 0 0 0 0
Bloating 2 2 0 0 2 2 0 0
GU
Frequency/urgency 1 1 1 1 0 0 0 0
Urinary retention 1 1 1 1 0 0 0 0
Cystitis 1 0 1 0 0 0 0 0
Other
Motor neuropathy/weakness 4 3 1 1 3 2 0 0
Sensory neuropathy 5 3 5 3 0 0 0 0
Lymph edema 4 4 2 3 2 1 0 0
Pain 2 3 2 3 0 0 0 0
Spondylodiscitis 1 0 0 0 0 0 1 0
GI: gastrointestinal, GU.genitourinary, yr: year, yrs: years.
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other groups investigating this rare disease, namely poor
accrual over a long time span. We therefore decided to
perform this unplanned interim analysis to evaluate
whether the initial aims of the study are still reasonably
achievable. With a median follow-up of 33 months, we
found encouraging local control and overall survival rates
(estimated 5-year LC 72%, and 5-year OS 74%), especially
given the unfavourable patient selection (median tumor
volume 1146 ccm and surgery with negative margins pos-
sible in only 22% of the patients). Moreover, we found a
change in the pattern of failure, with distant metastasis be-
ing more prevalent than local recurrences. However, two
recurrences were observed shortly after 5 years of follow-
up, indicating the need for longer follow up to draw de-
finitive conclusions. Nevertheless, our preliminary results
seem to compare favourably with other groups using simi-
lar approaches. Pawlik et al. [1] reported a combined
analysis of two prospective trials including 72 patients
with high grade retroperitoneal sarcomas treated with
preoperative radiation therapy and surgery. Preoperative
radiation was completed in 89% of the patients and 57
proceeded to surgery. Gross total resection was achieved
in 54 patients of whom 32 received an additional boost via
IORT or brachytherapy. With a median follow-up of
40 months, they observed 2- and 5-year local control rates
of 79% and 60% and a 5-year overall survival rate of 61%
after gross total resection. Gronchi et al. [24] reported a
prospective trial of 83 patients, who were treated by pre-
operative radiation therapy combined with chemotherapy.
Radiation therapy was completed as planned in 73 and an
additional IORT boost was given in 14 patients. 79 patients(95%) underwent surgery. With a median f/u of 58 months,
5-year local control, distant control and overall survival
rates were 63%, 74% and 59%, respectively. Smith et al. [25]
published the long term analysis of a prospective trial which
investigated preoperative radiation in 40 patients combined
with selectively applied postoperative brachytherapy. After
a median follow-up of 106 months, 5-year overall survival
was reported to be 70% with a crude local control rate of
68%. Tzeng et al. [26] reported a small prospective trial in-
vestigating dose escalated preoperative IMRT with inte-
grated boost in 16 patients. Gross total resection was
achieved in 14 patients, resulting in a 2-year local control
rate of 80% after a median f/u of 28 months. These results
were also supported by several retrospective series which
reported 5-year local control rates of 63-68% and 5-year
overall survival rates of 64-72% with similar approaches
[27-29], see Table 7. In summary, preoperative radiation
therapy followed by surgery with or without additional
boost consistently reached high local control and overall
survival rates, which seem to be superior to the results of
surgery alone or combinations of surgery with postopera-
tive radiation, although formal high level evidence is still
lacking. Therefore two phase III trials (ACOSOG Z9031,
EORTC 62092) have been designed to evaluate preopera-
tive radiation. While the first trial has already been closed
due to poor accrual [27], the results of the ongoing EORTC
trial are eagerly awaited and will hopefully clarify the role of
preoperative radiation therapy.
Besides oncological outcome, every additional therapy
comes along with toxicity. Therefore, the possible benefits
in terms of local control or overall survival have to be weighed
against side effects. In our study, mild gastrointestinal and
Table 7 Series with preoperative radiation therapy
Author Year Type n f/u Pre RT GTR Boost 5-year-LC 5-year-OS
Pawlik1 2006 Pro.,comb. 72 40 89% 79% 44% 60%* 61%*
Gronchi24 2014 Pro. 83 58 88% 95% 17% 63% 59%
Smith25 2014 Pro.,subgr. 40 106 100% 100% 48% 63% (cr) 70%
Tzeng26 2006 Pro. 16 28 100% 88% 0% (d) 80% (2 yr) n.s.
McBride27 2013 Retro. 33 33 100% 100% 30% 63% (3 yr) 64% (3 yr)
Sweeting28 2013 Retro. 18 43 94% 100% 100% 64% 72%
Alford29 2012 Retro. 24 28 100% 75% 0% 68% 54%
Present data 2014 Pro.,interim 27 33 93% 96% 85% 72% 74%
pro.: prospective trial, comb., combined analysis, subgr.: subgroup analysis, interim: interims analysis, n: number of patients, f/u: median follow-up in months, pre
RT: percentage of patients with completion of preoperative radiation therapy as planned, GTR: percentage of patients in whom gross total resection was achieved,
boost: percentage of patients who received an additional boost via IORT or Brachytherapy, d: preoperative radiation therapy was dose escalated, LC: local control,
OS: Overall survival, *: in grossly resected patients, cr: crude rate, 2 yr: 2-year rate, 3 yr: 3-year rate.
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diation therapy, but only 4 patients (15%) suffered from
grade III acute toxicity, which seems quite acceptable given
the large radiation fields (median tumor size 15 cm, median
PTV~ 2400 ccm). Jones et al. [30] described GI/pelvic
grade I toxicity in 34% and grade II in 47% with no grade
III side effects in their prospective trial on preoperative ra-
diation. Pisters et al. [31] reported a dose escalation trial
with simultaneously given doxorubicin and described high
rates of acute gastrointestinal grade III-IV toxicity (18%)
and hematological toxicity (27%) in patients treated at the
50.4 Gy dose level, although at least parts of the side effects
might be attributable to chemotherapy. Gronchi et al. [24]
also reported higher grade III/IV toxicity rates, but again
this trial included simultaneously applied chemotherapy
and therefore is difficult to compare. Caudle et al. [32]
found acute toxicity in 43% of 14 patients treated with pre-
operative radiation. From the description, it can be esti-
mated that the rate of severe acute side effects (grade 3 or
higher) was 21%, although toxicity was not formally graded.
Zlotecki et al. [33] compared patients with preoperative
and postoperative radiation and found significantly de-
creased severe acute side effects after preoperative radiation
therapy (36% vs 80%).
Preoperative radiation did not compromise the gen-
eral ability for surgery in our study, as all patients
proceeded to surgery and all except one received gross
total resection. However, we observed a considerable
rate (33%) of severe postoperative complications, in-
cluding 2 patients (7%) who finally died after multiple-
interventions in the prolonged postoperative period
(30 day postoperative mortality rate was 0%). Jones et al.
[30] reported severe postoperative complications in 41%
of their patients treated with preoperative radiation and
selectively applied brachytherapy. They further described
a 30 day mortality rate of 2%, but two additional patients
(4%) died during the following 18 months due to anasto-
motic leakage and duodenal perforation. Gronchi et al.[24] observed 21% major postoperative complications
after preoperative chemoradiation and Alford et al. [29]
found 44% severe postoperative complications after
preoperative radiation without additional boosting tech-
niques. These results raise the question, if preoperative ra-
diation increases the postoperative complication rate.
However, this question is difficult to answer, as data from
prospective series using surgery only is rare. Strauss et al.
[34] described a 30 day mortality rate of 3% after surgery
alone. Lewis et al. [35] reported a 30 day mortality rate of
4% in a large series of patients treated with surgery only
or additional radiation and chemotherapy. Bonvalot et al.
reported a mortality rate of 3% with only 18% of their pa-
tients requiring an invasive therapeutic procedure and
12% re-operation rate in a series treated with so called
“aggressive frontline surgery” [36]. About one third of the
patients had received preoperative radiation, but unfortu-
nately the complication rate was not reported separately for
the groups with or without radiation treatment. Zlotecki
et al. [33] compared pre- and postoperative radiation ther-
apy and observed a significant difference in severe postop-
erative morbidity (20% vs 53%) favouring the preoperative
approach. Finally, Bartlett et al. [37] compared preoperative
radiation with surgery alone in a large retrospective series
and found no significant differences, neither in overall mor-
bidity and mortality nor in specific side effects. Given the
extended surgical approach with contiguous organ resec-
tion in our patients, the postoperative complication rate
seems acceptable and at least not distinctly increased by
preoperative radiation. However, regarding the differences
in mortality rates covering different postoperative time
spans and the wide range of “severe” postoperative compli-
cations reported in the (mainly retrospective) literature
after surgery with or without radiation therapy, further
clarification is needed by standardized reporting of toxicity
data from prospective trials.
Severe late toxicity was uncommon in our study, as
only 1 patient (6%) showed grade III late toxicity at one
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[30] reported a 10% severe late toxicity rate at 18 months
and Smith et al. [25] described severe late toxicity in
11% of the patients after 18 months in an updated report
of the same trial with mature follow-up. Alford et al.
[29] observed late toxicities of any grade in 46% of their
patients. Interestingly, they described neurological lower
limb side effects in 21%, although no additional boost
via IORT has been performed, indicating that at least
parts of the neuropathy effects usually attributed to
IORT treatments might be caused by other reasons.
However, the low rate of neuropathy might been ex-
plained by the lower IORT doses used in our trial com-
pared to many other series. Based on the early findings
reported by Shaw et al., which described a significant as-
sociation between increased IORT dose and neuropathy
rate [20], the IORT dose was limited to 10–12 Gy in our
study protocol. Interestingly, Haddock et al. described a
significant reduction of neuropathy with intraoperative
doses of less than 12.5 Gy in a recently updated series of
rectal cancer treated with IORT [38], indicating that our
dose constraint seemed reasonable.
Clearly our analysis has some limitations mainly because
of its nature of an unplanned interim analysis due to slow
accrual. This naturally results in a relatively small number
of patients with short follow-up, thus limiting the ability
to draw definitive conclusions. Nevertheless, it represents
prospectively collected data for the combination of pre-
operative radiation therapy using IMRT followed by ag-
gressive surgery with contiguous organ resection and
intraoperative radiation therapy in this rare disease of
retroperitoneal sarcoma and therefore adds valuable infor-
mation to the small existing body of evidence for this
combination approach.
In summary, combination of preoperative IMRT, sur-
gery and IORT resulted in promising 5-year local control
and overall survival rates with low rates of acute and late
toxicity and acceptable postoperative complications. Long
term follow-up seems mandatory given the observation of
late recurrences. Accrual of patients will be continued
with extended follow-up.
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